| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | MI-1 | CTRPv2 | pan-cancer | AAC | 0.004 | 0.9 |
| mRNA | KPT185 | CTRPv2 | pan-cancer | AAC | 0.0038 | 0.9 |
| mRNA | BMS-536924 | GDSC1000 | pan-cancer | AAC | 0.0034 | 0.9 |
| mRNA | BRD-K28456706 | CTRPv2 | pan-cancer | AAC | -0.0034 | 0.9 |
| mRNA | Crizotinib | GDSC1000 | pan-cancer | AAC | -0.0048 | 0.9 |
| mRNA | PX-12 | CTRPv2 | pan-cancer | AAC | 0.0025 | 0.9 |
| mRNA | RITA | CTRPv2 | pan-cancer | AAC | -0.0031 | 0.9 |
| mRNA | etoposide | CTRPv2 | pan-cancer | AAC | -0.0026 | 0.9 |
| mRNA | fluvastatin | CTRPv2 | pan-cancer | AAC | 0.0031 | 0.9 |
| mRNA | navitoclax:sorafenib (1:1 mol/mol) | CTRPv2 | pan-cancer | AAC | 0.003 | 0.9 |